Nebilet Nebivolol 5mg 28 tabs

$27.00

Essential arterial hypertension. Chronic heart failure of mild or moderate severity, in addition to the standard methods of treatment of patients over the age of 70 years.

Free shipping. Delivery time is 2-6 weeks. Please, consider it before ordering.

Send payment manually throught paypal and get 15% discaunt. Feel free choosing this payment method during checkout process.

Description

Nebilet Nebivolol Composition:
active ingredient: nebivolol; 1 tablet contains nebivolol (as nebivolol hydrochloride) 5 mg; excipients: lactose; corn starch; croscarmellose sodium; hypromellose; polysorbate 80; cellulose microcrystalline; silicon dioxide colloidal; magnesium stearate.

Indications

– Essential hypertension

– Chronic heart failure (as adjunctive therapy to standard therapies in elderly patients – over 70 years).

 

Dosage & Administration

Essential hypertension. The dose is 1 tablet (5 mg of nebivolol) per day; it should be always at the same time, it is possible during the meal. The antihypertensive effect appears after 1-2 weeks of treatment, in some cases, the optimal effect is obtained only for 4 weeks. Nebilet can be given as monotherapy or with other antihypertensive drugs. At the moment, an additional antihypertensive effect has been observed only in the combined use with hydrochlorothiazide 12.5-25 mg.
Chronic heart failure. Nebilet Treatment should be started with a gradual increase in dose until the optimal individual maintenance dose.

Patients with renal insufficiency: the recommended initial dose is 2.5 mg / day. If necessary, the daily dose can be raised to 5 mg.
Patients with hepatic insufficiency: the experience of the drug in such patients is limited, so Nebivolol is contraindicated.
Patients over the age of 65 years: as dose titration is carried out on an individual basis, a dose adjustment is required.

 

Contradictions

Hypersensitivity to the active substance or other components of the preparation.

Liver failure or liver function limitations.

Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring administration of the active substances with a positive inotropic effect. sinus node weakness syndrome, including sinus block, AV-blockade II-III degree (without pacemaker).

Bronchospasm and asthma history.

Untreated pheochromocytoma. Metabolic acidosis.

Bradycardia (heart rate before treatment <60 u. / Min).

Arterial hypotension (systolic blood pressure <90 mm Hg. Art.).

Severe peripheral circulatory disorders.